BackVerastem Overview
Verastem Inc

Verastem Target Price

Analysts' average 12-month price target for Verastem is $12.

Get informed when a big investor buys or sells

+ Follow

Share Price

$7.62

Average Target Price

$12.4062.7% upside

5 analysts in the last 4 months

High: $15 | Low: $8

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-10Mizuho Securities$1370.6% upsideOpen
2026-08-07Guggenheim$1257.5% upsideOpen
2026-07-07RBC Capital$1483.7% upsideOpen
2026-06-24RBC CapitalLeonid Timashev$1596.9% upsideOpen
2026-06-23Jefferies$85% upsideOpen
2026-05-08BTIG$18136.2% upsideOpen
2026-05-08Industrial Alliance Securities$18136.2% upsideOpen
2026-03-05JefferiesClara Dong$19149.3% upsideOpen
2026-02-19Mizuho Securities$18136.2% upsideOpen
2025-10-29Mizuho Securities$1596.9% upsideOpen
2025-10-21Mizuho SecuritiesGraig Suvannavejh$1483.7% upsideOpen
2025-10-21H.C. WainwrightSwayampakula Ramakanth$1483.7% upsideOpen
2025-10-20RBC Capital$1370.6% upsideOpen
2025-03-24GuggenheimMichael Schmidt$1483.7% upsideOpen
2025-03-24H.C. Wainwright$1031.2% upsideOpen
2024-07-29Mizuho SecuritiesGraig Suvannavejh$78.1% downsideOpen
2024-05-24BTIGJustin Zelin$1370.6% upsideOpen
2022-04-15RBC CapitalGregory Renza$534.4% downsideOpen

Verastem (VSTM) FAQ

Verastem's target price stands at $12. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $12 for VSTM implies 62.7% upside versus today's price ($7.62). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Verastem's target price evolved across reporting periods, while the comparison chart places VSTM next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Verastem's reading of $12 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.